ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Arthritis Rheumatol · 2026-04-16

Phase 3b RCT in 451 adults with active psoriatic arthritis after one TNF inhibitor: ACR20 at week 24 was 58.6% with guselkumab every 4 weeks and 62.2% every 8 weeks vs 34.8% with placebo; adverse events 46.7%, 53.6% and 48.3%.

RCTn = 451
Ogdie et al. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study
Gastroenterology · Lancet Gastroenterol Hepatol · 2026-01-13

Phase 3 trial in 418 adults with moderately to severely active ulcerative colitis: subcutaneous guselkumab 400 mg induction gave week-12 clinical remission in 28% vs 6% with placebo (difference 21 points). Serious adverse events: 4% in each guselkumab group vs 12% placebo.

RCTn = 418
Long et al. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.